BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31732918)

  • 21. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
    Rangé G; Yayehd K; Belle L; Thuaire C; Richard P; Cazaux P; Barbou F; Köning R; Chassaing S; Teiger E; Berthier R; Decomis MP; Claudel JP; Delarche N; Brunel P; De Poli F; Dupouy P; Beygui F; Albert F; Collet JP; Montalescot G;
    Arch Cardiovasc Dis; 2014 Apr; 107(4):225-35. PubMed ID: 24794216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
    Brener SJ; Kirtane AJ; Stuckey TD; Witzenbichler B; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Mehran R; Parvataneni R; Brodie BR; Stone GW
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1450-7. PubMed ID: 27372190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Smoking on Platelet Reactivity and Clinical Outcomes After Percutaneous Coronary Intervention: Findings From the ADAPT-DES Study.
    Gupta R; Kirtane AJ; Liu Y; Crowley A; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e007982. PubMed ID: 31672031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).
    Valenti R; Marcucci R; Comito V; Marrani M; Cantini G; Migliorini A; Parodi G; Gensini GF; Abbate R; Antoniucci D
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1563-70. PubMed ID: 26386764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
    Li Y; Han Y; Zhang L; Jing Q; Wang X; Yan G; Ma Y; Wang G; Wang S; Chen X; Yang L; Zhu G; Liu H; Jiang T
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1127-33. PubMed ID: 22945767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study.
    Gao XF; Lu S; Ge Z; Zuo GF; Wang ZM; Wang F; Kong XQ; Chai DY; Chen SL; Zhang JJ
    BMC Cardiovasc Disord; 2018 May; 18(1):103. PubMed ID: 29793432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus.
    Mangiacapra F; Peace A; Barbato E; Patti G; Gatto L; Ricottini E; De Bruyne B; Di Sciascio G; Wijns W
    Platelets; 2014; 25(5):348-56. PubMed ID: 23971913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus.
    Noman A; Balasubramaniam K; Alhous MHA; Lee K; Jesudason P; Rashid M; Mamas MA; Zaman AG
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1195-1204. PubMed ID: 28029209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.
    Garg A; Rout A; Sharma A; Sargsyan D; Beavers T; Tantry U; Gurbel P; Rao SV; Kostis JB; Cohen M
    Prog Cardiovasc Dis; 2020; 63(3):243-248. PubMed ID: 32247786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
    Lewis JP; Backman JD; Reny JL; Bergmeijer TO; Mitchell BD; Ritchie MD; Déry JP; Pakyz RE; Gong L; Ryan K; Kim EY; Aradi D; Fernandez-Cadenas I; Lee MTM; Whaley RM; Montaner J; Gensini GF; Cleator JH; Chang K; Holmvang L; Hochholzer W; Roden DM; Winter S; Altman RB; Alexopoulos D; Kim HS; Gawaz M; Bliden KP; Valgimigli M; Marcucci R; Campo G; Schaeffeler E; Dridi NP; Wen MS; Shin JG; Fontana P; Giusti B; Geisler T; Kubo M; Trenk D; Siller-Matula JM; Ten Berg JM; Gurbel PA; Schwab M; Klein TE; Shuldiner AR;
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):203-210. PubMed ID: 31504375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
    Palmerini T; Calabrò P; Piscione F; De Servi S; Cattaneo M; Maffeo D; Toso A; Bartorelli A; Palmieri C; De Carlo M; Capodanno D; Barozzi C; Tomasi L; Della Riva D; Mariani A; Taglieri N; Reggiani LB; Bianchi R; De Rosa R; Mariani M; Podda G; Généreux P; Stone GW; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1117-27. PubMed ID: 25240538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting.
    Jin HY; Yang TH; Kim DI; Chung SR; Seo JS; Jang JS; Kim DK; Kim DK; Kim KH; Seol SH; Nam CW; Hur SH; Kim W; Park JS; Kim YJ; Kim DS
    Int J Cardiol; 2013 Sep; 167(5):1877-81. PubMed ID: 22682702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.
    Zhang D; Zhang X; Liu D; Liu T; Cai W; Yan C; Han Y
    Cardiovasc Diabetol; 2016 Mar; 15():50. PubMed ID: 27005817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study.
    Lattuca B; Silvain J; Yan Y; Pouillot C; Cuisset T; Cayla G; Henry P; Diallo A; Elhadad S; Rangé G; Lhermusier T; Boueri Z; Motreff P; Carrié D; Vicaut E; Montalescot G; Collet JP
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e007749. PubMed ID: 31694410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.
    Faggioni M; Baber U; Sartori S; Giustino G; Cohen DJ; Henry TD; Farhan S; Ariti C; Dangas G; Gibson M; Giacoppo D; Krucoff MW; Aquino M; Chandrasekhar J; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
    JACC Cardiovasc Interv; 2017 Apr; 10(7):645-654. PubMed ID: 28330641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
    Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome.
    Hochholzer W; Valina CM; Bömicke T; Amann M; Stratz C; Nührenberg T; Trenk D; Neumann FJ
    Thromb Haemost; 2015 Jul; 114(1):109-14. PubMed ID: 25832119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
    Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.
    Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM;
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.